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Abstract
Background: In this study, the Spondyloarthritis Research Consortium Canada (SPARCC) scoring method was used to
compare treatment methods in patients with axial spondyloarthritis (SpA), a form of sacroiliitis. MRI abnormalities in
bone marrow edema (BME) were compared before and after treatment in order to compare the efficacy of anti-TNF-α
and DMARD, alone or in combination, as treatments for sacroiliitis.
Methods: Fifty-six Chinese patients with axial SpA (mean age 22.6 years) were recruited. Patients were divided into
three groups according to different treatments (anti-TNF-α alone vs. DMARDs alone vs. combined anti-TNF-α and
DMARDs). MRI examinations were performed before and after treatment. The SPARCC score, clinically relevant AS
Disease Activity (ASDAS) indices, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were analyzed.
Results: After treatment, ASDAS and SPARCC scores, ESR, and CRP were significantly improved (P < 0.05) in the
anti-TNF-α monotherapy and combination groups; however, there were no statistically significant differences (P > 0.05)
in clinical disease activity and radiological inflammation of sacroiliac joint (SIJ) in patients in the DMARDs alone group.
SPARCC showed a correlation with ASDAS score pre-treatment, but not post-treatment. Furthermore, there were
significant changes (P < 0.05) in these patients with axial SpA after only 3 months of treatment. Follow-up studies of
patients who continued therapy for 4-6 months and 9-12 months revealed statistically significant differences from
baseline (P < 0.05).
Conclusions: SPARCC can be used to assess severity of disease pre-treatment. Anti-TNF-α treatment resulted in
effective reduction of disease activity and BME of SIJ after 3 months of therapy.
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Background
Spondyloarthritis (SpA) is a chronic, debilitating inflam-
matory rheumatic disease that affects axial and periph-
eral joints, organs, and other tissues. Epidemiology
surveys of patients with SpA in China have reported a
prevalence of SpA in the military of 0.45 %; however, the
pooled incidence and prevalence of SpA from studies
performed in civilian populations is 0.93 %. These
numbers are similar to the prevalence found in Cauca-
sian populations in Europe or the United States [1–11].
Sacroiliitis is the pathological sign and one of the early
manifestations of SpA [12]. The management of SpA is
extremely difficult. The traditional anti-rheumatic drugs
(disease-modifying anti-rheumatic drugs (DMARDs)) are
not clearly effective towards improving arthropathy of
the central axis. In addition, numerous adverse reactions
limit their clinical application. Biological agents such as
tumor necrosis factor alpha (TNFα) inhibitor have been
used in clinical research to treat ankylosing spondylitis
(AS), showing efficacy against disease reactiveness and
positive effects on joint function.
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During the 2013 European League against Rheumatism
(EULAR) meeting on spondyloarthropathy, it was de-
termined that inflammation demonstrated by magnetic
resonance imaging (MRI) and radiographic progression
should be considered when determining therapeutic goals.
Therefore, a standard assessment system is necessary for
evaluating imaging changes in the sacroiliac joint (SIJ) in
patients with SpA. In a study by Landewe et al. [13], the
Spondyloarthritis Research Consortium Canada (SPARCC)
system had a high level of inter-reader variability and
sensitivity to change. The AS working group of the Inter-
national Association for the Evaluation of Spinal Arthritis/
Outcome Measures in Rheumatology (ASAS/OMERACT)
proposed that MRI should be used as the first choice for
evaluation of spinal arthritis [14].
More and more studies have used the SPARCC scoring
system [15] to evaluate the efficacy of treatments in re-
ducing joint inflammation of patients with SpA. Previous
studies have shown a correlation between SPARCC
scores and clinical disease activity. Zhang et al. [16] de-
termined a correlation between the apparent diffusion
coefficient (ADC) and SPARCC scores. However, little
attention has been focused on the period in which bone
marrow edema (BME) of the SIJ should be evaluated
and the differences in joint inflammation changes be-
tween different therapies. Therefore, this study aimed to
investigate the value of the SPARCC scoring system in
evaluating the treatment of patients with axial SpA. Spe-
cifically, the efficacy of anti-TNFα and DMARDs as
treatments for sacroiliitis was assessed with both drugs
alone or in combination.
Methods
Patient eligibility
Fifty-six patients with SpA treated at the Guangdong
General Hospital between September 2012 and March
2014 were recruited. Inclusion criteria included meeting
the ASAS classification criteria for axial SpA [17]. The
Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) score had to be ≥4 [18]. No patient had been
treated with systemic glucocorticoids for a period of 3
months prior to the trial. Participation required that pa-
tients had no active infectious diseases or severe organ
function failure.
The 56 patients were divided into three groups accord-
ing to therapy type. There were 18 patients with SpA
treated using anti-TNFα alone, 21 patients treated using
anti-TNFα combined with DMARDs, and 17 patients
treated with DMARDs alone. All patients were allowed to
use nonsteroidal anti-inflammatory drugs (NSAIDs) dur-
ing the study as needed. The dose of anti-TNFα was grad-
ually reduced as the disease became under better control
(Ankylosing Spondylitis Disease Activity (ASDAS) indices
<1.3) [19]. The reduction in dosage was as follows: if the
patient’s ASDAS was <1.3 after 3 months of adequate
therapeutic dosage of anti-TNFα, the interval between in-
jections was extended (from 50 mg every week down to
50 mg every 10 days); and when ASDAS remained <1.3
after another 3 months of treatment, the interval was ex-
tended to 50 mg every 15 days. No patient discontinued
treatment before the end of the study, and the dose for
those who had undergone DMARD treatment remained
the same as at the beginning of the study. Patients under-
went MRI before and within 12 months after treatment.
Patients ever treated with anti-TNFα (total 39 patients,
including anti-TNFα monotherapy and anti-TNFα com-
bined with DMARDs) were divided into three subgroups
according to the period of MRI examination: Group A,
patients underwent MRI in their 3rd month of treatment
(n = 10); group B, patients underwent MRI during their
4th–6th month of treatment (n = 17); and group C, pa-
tients underwent MRI during their 9th–12th month of
treatment (n = 12).
The study was approved by the ethical committee of
Guangdong General Hospital, China (approval No.
2013005H(RE)). Written informed consents were ob-
tained from the participants.
MRI scan
All patients’ SIJs were examined using T1-weighted im-
ages (T1WI), T2 fast-suppressed (T2-fs), and short-tau
inversion recovery (STIR). The BME of the SIJ was
scored by two experienced radiologists (10 and 2 years
of experience, respectively) according to the SPARCC
sacroiliitis scoring system. Readers were blinded to treat-
ment and time sequence of the images. Final scores were
taken as the average of the two readers.
SPARCC scoring system
The radiologists observed an increased signal in the iliac
bone and sacrum in six consecutive slices through the
SIJ on T2-fs images or STIR sequences on oblique cor-
onal slices. These slices comprise most of the synovial
compartment. Each SIJ is divided into four quadrants,
and each quadrant has 1 point for the presence of an in-
creased STIR signal. Next, a total score of 48 is obtained
from the six slices of the two SIJs. Then, 1 point is added
for each SIJ exhibiting an intense signal (compared with
the signal from adjacent blood vessels) or depth of BME
≥1 cm for the six slices, bringing the total score to 72.
Clinical evaluation
The ASDAS [19] included back pain, general condition,
and stiffness using a visual analog score, which was de-
termined by doctor inquiry and patient self-reporting.
C-reactive protein (CRP) and the erythrocyte sedimenta-
tion rate (ESR) were determined for all patients. For as-
sessment of the ESR, 5 ml blood were obtained from the
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median antebrachial vein of each patient after a 12-
hour fast and kept at 4 °C. Then, a 1.6 ml blood sample
was combined with 0.4 ml sodium citrate (109 mmol/l)
and the mixture was placed into an ESR tube taking
care not to create bubbles. The tube was placed verti-
cally on the ESR stand and the ESR was read after an
hour. For CRP, the blood sample underwent coagula-
tion and was centrifuged. The serum was taken and
kept at 4 °C. CRP levels were measured using a Roche
Cobas 6000 c501 automatic analyzer (Roche Diagnostics,
Laval, Canada) based on an immunoturbidimetry method,
using the reagents and instructions provided by the
manufacturer.
Treatment adverse effects were recorded based on the
reports from the patients, clinical examination, and rele-
vant biochemistry indexes.
Statistical analysis
Factorial analysis was used for inter-group comparisons
using SPSS 16.0 (IBM, Armonk, NY, USA). Intragroup
comparisons were performed with a paired t test or rank
Table 1 Patient characteristics and disease parameters
All Anti-TNF alone Anti-TNF + DMARDs DMARDs alone
Age (years) 21 (15–36) 23 (15–29) 27 (18–32) 28 (22–36)
Gender (male/female) 12/44 3/15 6/15 3/14
Disease duration 2 (0.17–10) 0.67 (0.17–3) 2 (0.75–6) 7.5 (3.5–10)
HLA-B27-positive 91.1 % (51/56) 88.9 % (16/18) 90.5 % (19/21) 94.1 % (16/17)
Baseline
SPARCC 32.45 ± 18.71 27.76 ± 18.38 39.53 ± 19.21 28.67 ± 15.51
ASDAS 2.84 ± 1.26 2.56 ± 1.24 3.58 ± 1.05 2.21 ± 1.03
ESRa 27.10 ± 32.39 27.94 ± 33.24 38.49 ± 38.50 12.14 ± 8.43
CRPa 17.50 ± 23.07 16.29 ± 23.05 26.29 ± 28.02 7.919 ± 5.60
aNot normally distributed, compared by paired rank test
ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate,
SPARCC Spondyloarthritis Research Consortium Canada, TNF tumor necrosis factor
Table 2 Differences of indexes in patients with different treatment method
Index Baseline (mean ± SD) Post-treatment (mean ± SD) t/Z P
Patients treated by anti-TNF alone (n = 18)a
SPARCC 27.76 ± 18.38 14.38 ± 14.91 2.681 0.011
ASDAS 2.56 ± 1.24 1.83 ± 0.71 4.231 0.006
ESRb 27.94 ± 33.24 5.72 ± 7.06 –2.763 0.009
CRPb 16.29 ± 23.05 2.70 ± 2.55 –2.470 0.022
Patients treated by anti-TNF combined with DMARDs (n = 21)c
SPARCC 39.53 ± 19.21 20.71 ± 15.98 5.110 0.000
ASDAS 3.58 ± 1.05 1.88 ± 0.74 4.278 0.003
ESRb 38.49 ± 38.50 9.02 ± 13.29 –2.703 0.010
CRPb 26.29 ± 28.02 8.43 ± 15.79 –2.329 0.053
Patients treated by DMARDs alone (n = 17)d
SPARCC 28.67 ± 15.51 21.66 ± 11.23 0.820 0.419
ASDAS 2.21 ± 1.03 1.99 ± 0.47 1.301 0.261
ESRb 12.14 ± 8.43 4.65 ± 4.27 –2.396 0.013
CRPb 7.919 ± 5.60 5.55 ± 4.46 –1.911 0.056
aBaseline of clinical practices from patients in anti-TNF group: 85.7 % male; age, 23.3 ± 6.43; symptom duration, 3.15 ± 2.98; HLA-B27-positive, 100 %
bNot normally distributed, compared by paired rank test
cBaseline of clinical practices from patients in combination group: 82.35 % male; age, 21.6 ± 3.36; symptom duration, 2.97 ± 2.69; HLA-B27-positive, 88.2 %
dBaseline of clinical practices from patients in DMARD group: 80 % male; age, 20.5 ± 2.75; symptom duration, 3.0 ± 2.66; HLA-B27-positive, 90 %
ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate,
SD standard deviation, SPARCC Spondyloarthritis Research Consortium Canada, TNF tumor necrosis factor
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sum test and nonparametric test. Two-sided P <0.05 was
considered statistically significant.
Results
Patient age ranged from 15 to 45 years; average patient
disease duration was from 2 months to 10 years. Charac-
teristics of the patients are presented in Table 1.
MRI scans
For the seven (17.9 %) patients treated with anti-TNFα,
BME completely disappeared within 12 months. Similar
outcomes were observed in patients treated with anti-
TNFα alone or in combination with DMARDs; for these
patients, there was a significant decrease in their
SPARCC scores within 12 months of treatment (P <
0.05) (Table 2 and Figs. 1 and 2). Nevertheless, for pa-
tients treated by DMARDs, SPARCC scores did not
change after treatment (P = 0.419) (Table 2 and Fig. 3).
Patients treated with anti-TNFα alone showed de-
creased SPARCC scores, ASDAS indices, ESR, and CRP
within 12 months of starting treatment. SPARCC scores,
ASDAS indices, and ESR were significantly decreased
within 12 months after treatment with anti-TNFα
combined with DMARD therapy. However, there were
no significant differences in SPARCC scores, ASDAS in-
dices, ESR, or CRP for patients treated with DMARDs
alone within the 12-month study period (Table 3).
In detail, SPARCC scores in Group A were signifi-
cantly decreased after 3 months of full-dose anti-TNFα
(P = 0.012). In Group B (4–6 months of full-dose anti-
TNFα), SPARCC values were reduced (P = 0.001). In
Group C, patients were treated 9–12 months of anti-
TNFα, and the values were also reduced (P = 0.038). The
correlation between ASDAS values and MRI values was
assessed, showing good correlation pre treatment but
not after treatment (Fig. 4).
Adverse effects
Two patients experienced adverse reactions in the form
of a temporary rash at the area of injection. One subject
experienced a mild rash after oral sulfasalazine (SASP)
intake. The diameters of the rashes were less than 5
mm, mild, without skin ulceration, and lasted for only 2
days without any treatment. One patient experienced a
urinary tract infection during the second month of anti-
TNFα treatment, caused by Escherichia coli. The patient
Fig. 1 BME changes a before (SPARCC score 65) and b after 6 months of anti-TNFα monotherapy (SPARCC score 22)
Fig. 2 BME changes a before (SPARCC score 72) and b after 6 months of treatment with anti-TNFα combined with DMARDs (SPARCC score 13)
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was treated with levofloxacin for 2 weeks based on re-
sults from a bacterial culture. Two patients experienced
mild liver function abnormalities (patient 1, ALT = 42 U/l;
patient 2, AST = 57 U/l). Liver function returned to nor-
mal after 2 weeks of liver treatment.
Discussion
NSAIDs and anti-rheumatic drugs are the primary treat-
ment for SpA. SASP is believed to reduce the ESR and
morning stiffness [20]. The pathogenesis of SpA is com-
plex. Recent studies have revealed that TNFα plays a key
role in the development of the disease. Studies have
shown that TNF antagonists can significantly improve
both disease activity and joint function [20–25].
In this study, patients with high SpA activity treated
by targeted therapy (including etanercept, infliximab,
and adalimumab) for 3 months showed significantly de-
creased ASDAS indices, SPARCC scores, and ESR (P <
0.05), indicating that 3 months of full-dose anti-TNFα
therapy have significant efficacy as treatment against
SpA. Furthermore, there was obvious resorption of SIJ
acute inflammatory lesions observed from MRI examin-
ation. In 2013, an expert advisory committee advised the
use of etanercept for the treatment of rheumatoid
Fig. 3 BME changes a before (SPARCC score 36) and b after 8 months of DMARDs monotherapy (SPARCC score 33)
Table 3 Differences of indexes in patients at different treatment periods
Index Baseline (mean ± SD) Post-treatment (mean ± SD) t/Z P
Group A: 3 months of full-dose anti-TNFα (n = 10; n = 6 for anti-TNFα alone, n = 4 for combination)a
ASDAS 3.43 ± 1.55 1.66 ± 0.40 2.675 0.043
SPARCC 31.67 ± 18.64 14.50 ± 18.41 3.768 0.012
ESRb 52.00 ± 43.83 5.00 ± 5.55 –2.023 0.046
CRPb 36.58 ± 40.37 1.92 ± 1.09 –1.782 0.083
Group B: 4–6 months of anti-TNFα (n = 17; n = 4 for anti-TNFα alone, n = 13 for combination)c
ASDAS 2.46 ± 0.58 1.58 ± 0.69 4.920 <0.001
SPARCC 34.98 ± 18.93 18.54 ± 15.72 4.285 0.001
ESRb 27.77 ± 34.95 7.22 ± 12.31 –2.749 0.007
CRPb 16.34 ± 23.11 4.37 ± 17.87 –2.283 0.025
Group C: 9–12 months of anti-TNFα (n = 12; n = 6 for anti-TNFα alone, n = 6 for combination)d
ASDAS 2.91 ± 0.89 2.05 ± 1.21 2.517 0.042
SPARCC 38.24 ± 15.39 23.09 ± 15.65 2.527 0.038
ESRb 28.29 ± 27.77 12.43 ± 13.57 –1.498 0.128
CRPb 14.43 ± 11.65 10.81 ± 16.54 –1.529 0.134
aBaseline of clinical practices from patients in Group A: 85.7 % male; age, 23 ± 5.62; symptom duration, 2.6 ± 3.25; HLA-B27-positive, 85.7 %
bNot normally distributed, compared by paired rank test
cBaseline of clinical practices from patients in Group B: 85.7 % male; age, 23.3 ± 6.43; symptom duration, 3.15 ± 2.98; HLA-B27-positive, 100 %
dBaseline of clinical practices from patients in Group C: 80 % male; age, 21.3 ± 2.53; symptom duration, 3.97 ± 3.52; HLA-B27-positive, 90 %
ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate,
SD standard deviation, SPARCC Spondyloarthritis Research Consortium Canada, TNFα tumor necrosis factor alpha
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arthritis and AS [26], and suggested that assessment of
treatment efficacy in patients with AS should be per-
formed at least 3 months after starting the treatment.
Based on the present study, anti-TNFα could be of great
help in improving the symptoms of SpA. After 3 months
of anti-TNFα, the clinical activity and BME of the SIJ in
patients with SpA showed significant improvement, and
patients might maintain remission with continued use,
even with a reduction in treatment dose. As shown in
this study, both anti-TNFα alone and in combination
with DMARDs showed significant changes in SPARCC
scores, ASDAS indices, and ESR. Previous studies [26–28]
showed that there were differences of SPARCC score in
disease-dormant patients and in disease-active patients.
Furthermore, the SPARCC score has been proven to be
positively correlated with the BASDAI, suggesting that the
SPARCC scoring system can be used to assess inflamma-
tion activity in SpA. The SPARCC scoring system there-
fore plays an important role in evaluating treatment
efficacy. The SPARCC scoring system provides a reference
for imaging and evaluating the efficacy of different therap-
ies. SIJ MRI examination has high sensitivity for the early
stages of sacroiliitis [29], and it is safer and easier to repeat
than X-ray or computed tomography scan.
There were some limitations to this study. The sample
size was small and the timing of MRI examinations was
not similar for all patients. Furthermore, the treatment
dose levels varied between participants. In this study,
DMARDs seem to have a modest effect at best on SpA,
but this study was not designed to examine the efficacy
of DMARDs. The results suggest that only a 3-month
follow-up might be necessary to assess the response to
treatment, and that subsequent follow-ups are relatively
optional. However, this study was not designed to ad-
dress this issue, and we cannot draw any conclusion on
this point. Additional multicenter trials are necessary to
determine adequately the usefulness of anti-TNFα and
the SPARCC scoring system in patients with SpA.
Conclusions
The SPARCC scoring system is a good index for show-
ing the severity of sacroiliitis pre treatment. In addition,
this study showed that anti-TNFα was effective in redu-
cing BME of the SIJ examined by MRI.
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